News Archive

Walbrook PR are pleased to announce its appointment as Financial PR advisor to Healthcare Investment Opportunities Plc , to manage communications with the financial media, research analysts and investors surrounding its Placing to raise £4m and Admission to AIM this morning.

The Board of Healthcare Investment Opportunities (AIM: HIO), and in particular David Evans (Chairman), have an extensive contact base and a proven record of creating value for investors through building businesses in the healthcare sector via a combination of organic and acquisitive growth. Examples include Axis Shield, BBI Holdings plc, DxS Ltd, EKF Diagnostics Holdings Plc, Epistem Holdings Plc, Scancell Holdings Plc and Sirigen Group Ltd. The rest of the Board is made up of Kevin Wilson (Non-Executive Director) and Malcolm Gillies (Non-Executive Director)

The £4m raised will be used for working capital whilst the Board seek suitable investments and, where applicable, acquisitions in line with the Company's Investment Policy. The Company will seek to acquire a business which is revenue generating or near revenue generating, has its own embedded or protected IP, is UK based, capable of significant growth and a credible management team.

The Board has identified a number of potentially interesting investment opportunities, although formal discussions in respect of any of these opportunities have not yet commenced. The Board anticipates the first acquisition will be a reverse takeover. They may also consider making other smaller acquisitions or investments although the Directors do not intend to create a portfolio of unconnected companies.

The Company's Admission document is available on the Company's website:

www.healthcareinvestmentopps.co.uk

Paul McManus, Director of Walbrook PR, said: "We are very pleased to work with the Healthcare Investment Opportunities team, having worked closely with David Evans over the last 8 years on a number of his successful Healthcare businesses. The recent addition of Mike Wort and Anna Dunphy to our Life Sciences team, who also advise Epistem where David Evans is Chairman, reinforces our strong position in the Healthcare space."